NCT03194542 2023-08-24
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
Celgene
Phase 2 Completed
Clinical Trials
79 trialsNCT04939558 2023-06-02
CARES
TidalSense
Completed
NCT01736683 2022-10-24
Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04076943 2022-06-03
Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia
Kyntra Bio
Phase 2 Completed
NCT02631070 2021-12-17
MEDALIST
Celgene
Phase 3 Completed
NCT02930850 2019-04-08
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Masimo Corporation
Phase NA Completed
NCT03776032 2018-12-20
A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy
Amgen
Phase 3 Completed
NCT01340976 2018-10-03
A Phase 1 Study of LY2787106 in Cancer and Anemia
Eli Lilly and Company
Phase 1 Completed
NCT02761642 2018-08-24
A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy
Hoffmann-La Roche
Phase 2 Completed
NCT00338286 2018-03-19
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Janssen Research & Development, LLC
Phase 3 Completed
NCT00236951 2018-02-20
Intravenous (IV) Iron vs. No Iron as the Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Therapy
American Regent, Inc.
Phase 3 Completed
NCT00711958 2017-09-05
Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients
Sandoz
Phase 3 Completed
NCT00776425 2017-07-02
A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies
Hoffmann-La Roche
Phase 4 Completed
NCT02767765 2017-04-04
A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy
Hoffmann-La Roche
Phase 3 Completed
NCT01444456 2017-03-20
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Amgen
Completed
NCT02554942 2016-11-02
A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors
Hoffmann-La Roche
Phase 4 Completed
NCT02564094 2016-11-02
A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies
Hoffmann-La Roche
Phase 4 Completed
NCT01809314 2016-08-19
An Observational Study of Epoetin Beta (NeoRecormon) in Participants With Cancer Receiving Chemotherapy
Hoffmann-La Roche
Completed
NCT01716559 2016-08-18
An Observational Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Non-myeloid Malignancy
Hoffmann-La Roche
Completed
NCT00327535 2016-08-11
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
Hoffmann-La Roche
Phase 2 Completed
NCT01374373 2016-04-07
Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia
Bio Sidus SA
Phase 4 Completed
NCT01795690 2016-02-29
TAR
iOMEDICO AG
Completed
NCT01168349 2015-10-02
An Observational Study of NeoRecormon (Epoetin Beta) in Cancer Patients With Anemia (FAST)
Hoffmann-La Roche
Completed
NCT00212862 2014-06-30
DOSE
Ortho Biotech Products, L.P.
Completed
NCT01691040 2014-06-26
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer
TME Pharma AG
Phase 2 Completed
NCT01018043 2014-05-23
Thai Cancer Anemia Survey in Chulalongkorn Hospital
Janssen-Cilag Ltd.,Thailand
Completed
NCT00264108 2014-05-07
Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia
Janssen-Cilag B.V.
Completed
NCT00264095 2014-04-28
An Observational Study of Blood Management Techniques in Oncology Surgical Treatment
Janssen-Cilag B.V.
Completed
NCT01030159 2014-04-09
National Cancer Institute Thai Cancer Anemia Survey
Janssen-Cilag Ltd.,Thailand
Completed
NCT00401544 2014-01-29
Darbepoetin Alfa With or Without Intravenous (IV) Iron
Amgen
Phase 2 Completed
NCT01101399 2013-12-18
FID-CHEMO
Vifor Pharma
Phase 3 Completed
NCT00144131 2013-05-24
Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy
Amgen
Phase 2 Completed
NCT00148421 2013-05-15
Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.
Amgen
Phase 3 Completed
NCT00035607 2013-05-13
Chemotherapy Related Anemia
Amgen
Phase 2 Completed
NCT00091858 2013-05-08
Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer
Amgen
Phase 3 Completed
NCT00111462 2013-05-08
Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy
Amgen
Phase 2 Completed
NCT00540384 2013-05-08
Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle Chemotherapy
Amgen
Phase 1/2 Completed
NCT00118638 2013-04-29
A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
Amgen
Phase 3 Completed
NCT00540696 2013-04-26
Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa
Amgen
Phase 2 Completed
NCT00097747 2012-12-21
Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers
Affymax
Phase 1 Completed
NCT00272662 2012-12-21
Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy
Affymax
Phase 2 Completed
NCT00398749 2012-11-06
Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)
Janssen-Cilag B.V.
Completed
NCT00359840 2012-08-31
A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT01394991 2012-04-05
A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 4 Completed
NCT00224068 2012-03-02
Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy
Watson Pharmaceuticals
Phase 4 Completed
NCT00210587 2011-06-10
An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00210600 2011-06-10
Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00210834 2011-06-10
An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00337948 2011-06-10
An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00338416 2011-06-10
An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed